The tale of TILs in breast cancer : A report from The International Immuno-Oncology Biomarker Working Group

Show full item record



Permalink

http://hdl.handle.net/10138/340630

Citation

The International Immuno-Oncology Biomarker Working Group , El Bairi , K , Haynes , H R , Blackley , E , Almangush , A , Makitie , A , Joensuu , H & Lundin , J 2021 , ' The tale of TILs in breast cancer : A report from The International Immuno-Oncology Biomarker Working Group ' , Npj breast cancer , vol. 7 , no. 1 , 150 . https://doi.org/10.1038/s41523-021-00346-1

Title: The tale of TILs in breast cancer : A report from The International Immuno-Oncology Biomarker Working Group
Author: The International Immuno-Oncology Biomarker Working Group; El Bairi, Khalid; Haynes, Harry R.; Blackley, Elizabeth; Almangush, Alhadi; Makitie, Antti; Joensuu, Heikki; Lundin, Johan
Contributor organization: Department of Pathology
HUS Head and Neck Center
Clinicum
Korva-, nenä- ja kurkkutautien klinikka
Heikki Joensuu / Principal Investigator
HUS Comprehensive Cancer Center
Department of Oncology
Johan Edvard Lundin / Principal Investigator
Institute for Molecular Medicine Finland
University of Helsinki
Date: 2021-12
Language: eng
Number of pages: 17
Belongs to series: Npj breast cancer
ISSN: 2374-4677
DOI: https://doi.org/10.1038/s41523-021-00346-1
URI: http://hdl.handle.net/10138/340630
Abstract: The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
Description: Publisher Copyright: © 2021, The Author(s).
Subject: 3122 Cancers
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
The_tale_of_TILs_in_breast_cancer_A_re...pdf 6.039Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record